| Detailed information |
|---|
| CancerLivER ID | 2241 |
| Biomarker | DANCR |
| Biomarker Name/Symbol (given in Publication) | DANCR |
| Biomolecule | LncRNA |
| Subject | Human |
| Degree of Validity | DANCR in clinical diagnosis and disease progression of HCC and validated on independent dataset |
| Experimental Condition | HCC v/s Normal/Cirrhosis/CHB;associated with metastasis of patients |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in HCC |
| Level of significance | p < 0.001 |
| Source | Plasma |
| PMID | 27919960 |
| Type of Biomarker | Diagnostic and Prognostic |
| Pathway | NA |
| Cohort | 146 participants including healthy volunteers (HVs) and patients with chronic hepatitis B (CHB), cirrhosis and HCC: healthy volunteers (HVs) (n=43) and patients with chronic hepatitis B (CHB) (n=29), cirrhosis (n=22) and HCC (n=52).; HCC cell lines SMMC-7721 and HCCLM3 |
| Sensitivity | 80.80% |
| Specificity | 84.30% |
| Accuracy | NA |
| AUC | 0.868 |
| Disease | Human HCC |
| Year of Publication | 2016 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |